Purpose: The epidermal growth factor receptor (EGFR) plays an important role in cellular response to chemotherapy and radiotherapy through modulation of DNA repair. EGFR activates DNA-dependent protein kinase (DNA-PK) stimulating repair of DNA strand breaks (SB) and interstrand crosslinks (ICL). We investigated the role of EGFR in repair of ionizing radiation (IR)-induced SB independently of DNA-PK.
Introduction
The epidermal growth factor receptor (EGFR) is a potent driver of cellular proliferation, survival and motility and, together with the other members of the ERBB family, it determines critical cellular signaling events (1) . Deregulation of EGFR in cancer arises from overexpression, gene amplification, and somatic mutations (2, 3) . These occur in glioblastoma, breast, head and neck, and non-small cell lung cancer (NSCLC; refs. 4, 5) . Targeted inhibition of EGFR using tyrosine kinase inhibitors (e.g., gefitinib and erlotinib) and monoclonal antibodies (e.g., cetuximab) are in clinical use as monotherapy or in combination with chemotherapy and ionizing radiation (IR; refs. 6, 7). In contrast to results obtained for combinations of EGFR inhibitors and chemotherapy in vitro, clinical results have rarely shown synergy of these combinations. The study of these combinations has indicated a role for EGFR in DNA repair. Genotoxic stress can induce EGFR autophosphorylation activating signaling pathways that promote proliferation (p38MAPK/MAPK/ JNK) and survival (AKT/XIAP/NF-kB; refs. 8, 9) , but EGFR can also modulate DNA damage response by interacting with components of the DNA repair machinery (10) . Cisplatin and IR treatments induce association of EGFR with the catalytic subunit of the DNA-dependent protein kinase (DNAPKcs), a major component of non-homologous end joining (NHEJ; refs. 11, 12) . This association enhances kinase activity of the DNAPK complex increasing the repair of DNA strand breaks (SB; refs. 11, 13, 14) . In addition, EGFR can also directly activate the proliferation cell nuclear antigen, essential for the DNA sliding clamp involved in DNA replication and DNA repair (15) .
Expression of nuclear EGFR has been shown to correlate with overall survival in breast cancer, decreased disease-free survival in oropharyngeal squamous cell carcinoma, and with tumor node metastasis in esophageal cancer (16, 17) . Understanding the relationship between sensitivity to cancer therapy and the role of EGFR in DNA repair is therefore important for design of novel therapeutic combination strategies.
In this study, analysis of glioma cell lines expressing DNAPKcs (M059K) or deficient in DNAPKcs expression (M059J) revealed that EGFR inhibition impairs IR-induced DNA SB repair in cells lacking expression of DNAPKcs, suggesting a role for EGFR in repair of SB independent of DNAPKcs. Following screening of potential binding partners using mass spectrometry, we validated a novel interaction of EGFR with the excision repair complement group protein 1 (ERCC1). There is evidence that ERCC1-XPF is involved in the repair of cisplatin adducts (18) (19) (20) (21) . The complex is required for the 5 0 incision at the junction between double stranded DNA and a 3 0 single stranded region, necessary for the unhooking of ICLs, and also for DNA resynthesis to fill the gap left by the incision (22) . Recent work has also shown the involvement of this complex in IR-induced SB repair via a NHEJ-independent backup mechanism (23, 24) .
This study investigates the significance of the EGFR-ERCC1 interaction in IR-induced DNA damage response and demonstrates biologic function in DNA repair independently of NHEJ. Understanding alternative mechanisms employed by EGFR-overexpressing cancer cells to repair therapy-induced DNA damage will inform design of targeted therapies involving combinations of EGFR inhibitors and DNA-interactive therapeutic agents.
Materials and Methods

Materials
Clinical grade gefitinib (Iressa/ZD1839; 10 mmol/L) was obtained from AstraZeneca. NU7026 (1 mmol/L) was obtained from Selleckchem.
Irradiation conditions
Cells were plated at a concentration of 2 5 Gy per minute, with a total dose of 15 Gy (comet assay) using A.G.O. HS 321kV X-ray system. After irradiation, cells were placed in the incubator and samples were collected in lysis buffer (WB, IP), or in serum-free media (Comet assay) or fixed with 4% PFA (IF, PLA) at the indicated time points.
Cell line and culture conditions M059K and M059J cell lines were a kind gift from Dr. Ricky Sharma (Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, UK). BON1 (human endocrine pancreatic tumor cell line) cells were obtained from the CRUK cell line repository and were a kind gift from Dr. Christina Thirlwell (UCL Cancer Institute, London, UK). QGP1 (human pancreatic endocrine cell line) cells were obtained from Japan Health Sciences Foundation. M059K, M059J, and BON1 were grown in Dulbecco's minimal essential medium (Autogen Bioclear), QGP1 were grown in RPMI-1640 medium (Autogen Bioclear). All cells were supplemented with 10% fetal calf serum and 1% glutamine and incubated at 37 C in 5% CO 2 .
siRNA transfection Cells were plated at a concentration of 2 Â 10 4 /mL. Twentyfour hours after plating, cells were then transfected with 25 nmol of ON-TARGETplus SMARTpool siRNA targeting ERCC1, EGFR or ERCC1, and EGFR (EGFR-ERCC1; Thermo Scientific) according to the Dharmafect transfection reagent protocol (Dharmacon). Cells were then treated for 48 hours following transfection with 1 mmol/L gefitinib or 125 nmol/L NU7026 for 1 hour before 4 Gy ionizing radiation.
Alkaline single-cell gel electrophoresis (comet) assay DNA strand break repair in cells irradiated with 15 Gy was measured using the comet assay as previously described (25) . Data were presented as a percentage of tail moment, i.e., as a percentage of the amount of strand breaks resulting immediately after IR treatment.
Immunoprecipitation
M059K, M059J, BON1, and QGP1 lines were plated at 2 Â 10 5 /mL (Twenty 15 cm dishes per cell line) and left 24 to 36 hours before treatment. Cells were then treated with 4 Gy IR. Twenty minutes after IR, approximately 10 7 cells/dish were lysed in 500 mL of CelLytic M Cell lysis reagent (Sigma) supplemented with protease and phosphatase inhibitor (Roche) and Benzonase (Merck) according to manufacturer's protocol. Two milligrams of protein sample was incubated with 2.5 mg of anti-EGFR antibody (clone R19/48 Invitrogen) or anti-ERCC1 antibody (clone D-10 Santa Cruz Biotechnology) and left rotating at 4 C overnight. Immunoprecipitation was performed as previously described (26) .
Translational Relevance
The epidermal growth factor receptor (EGFR) is an important target for therapy in several solid tumors. However, combinations of EGFR-targeting small molecules and antibodies with DNA-interactive agents have only been modestly successful. To further understand the role of EGFR modulation in radiation-induced DNA damage repair, we performed mass spectrometry in cells expressing and lacking DNA-dependent protein kinase (DNA-PK), which has previously been implicated in the EGFR-mediated response to both radiation and chemotherapy. In this study, we identified the novel interaction of the excision repair cross-complementation group 1 (ERCC1) with EGFR as being an important modulator of repair of DNA strand breaks induced by radiation treatment. Using a variety of techniques we demonstrated that this interaction plays a key role in DNA repair and sensitization of cells to radiation independently of DNA-PK. Understanding the significance of EGFR-ERCC1 interaction will be important in optimizing combination treatments for cancers where both EGFR and ERCC1 are expressed.
Western blotting
Western blotting was performed as previously described (11) . Antibodies used were anti-EGFR (Cell Signaling Technology; 1:1,000), anti-ERCC1 (clone D-10; Santa Cruz Biotechnology, Cell Signaling Technology, 1:1,000) anti-XPF (1:400, kind gift of Dr. Rick Wood, MD Anderson Cancer Center, University of Texas, Houston, TX). Finally, the primary antibody was probed with horseradish peroxidase-conjugated polyclonal antibodies for chemiluminescence detection (ECL System, Amersham Biosciences).
Immunofluorescence staining
A total of 2 Â 10 4 cells were plated on 13 mm glass cover slips (VWR). Cells were then treated with IR as detailed above and stained as previously described (11) . Respective primary antibodies were added as follows: anti-rabbit EGFR (1:50, clone D38B1 Cell Signaling Technology) and anti-mouse ERCC1 (1:50 clone D-10 Santa Cruz Biotechnology) and anti-mouse gH2AX (1:1,000 Millipore). Secondary fluorescent-conjugated antibodies were then added as follows: 1:100 Alexa Fluor 488 goat anti-rabbit and 1:100 Alexa Fluor 647 goat anti-mouse or 1:1,000 Alexa Fluor 488 goat anti mouse (for gH2AX; Molecular Probes and Invitrogen Life Technologies). Cells were visualized by confocal microscopy (objective Â40, Leica TCS SP2). Nuclear slice images were acquired by sequential scanning using the LAS AF Lite programme. gH2AX foci were counted via ImageJ with the inner nuclear particle extension. Green fluorescent events (gH2AX) in the nuclei were counted by assigning to one single focus the correspondent size of 3 pixels. The programme then generated inner nuclear events per single nucleus.
Proximity ligation assay
Proximity ligation was performed according to the manufacturer's protocol using the Duolink Detection Kit (Cambridge BioScience Ltd). Immunofluorescence staining of EGFR and ERCC1 for the Duolink was carried out following the above described protocol until the primary antibody incubation step. Probes incubation, ligation, and amplification reaction were carried out according to manufacturer instructions. Cy3 signal amplification was utilized for the assay. Cells were examined with a confocal microscope (objective Â 40, Leica TCS SP2).
MTT assay
MTT assay was performed as previously described (27) . A total of 2 Â 10 3 cells were plated in 96-well plates (Corning). Forty-eight hours after siRNA transfection, cells were treated with the gefitinib and NU7026 for 1 hour, before 4 Gy IR. Viability was then assessed 72 hours after treatment.
Caspase-3 cleavage assay
Caspase-3 cleavage was determined according to the Caspage Glo assay (Promega).
Statistical analysis
The two-way ANOVA, Bonferroni post test, and Student t tests were used for calculating the significance of the differences in repair and survival assays. All cell lines were considered individually and compared to the nontargeting siRNA control. Statistical values of P < 0.05 were considered significant.
Results
EGFR modulates DNA repair independently of DNAPKcs
The role of EGFR binding to DNAPKcs in the modulation of DNA repair has been described (11) . However, involvement of EGFR in pathways of DNA repair independent of DNAPK has not been clearly defined. To investigate potential additional roles for EGFR in modulation of DNA repair, the human glioma cell lines M059K (DNAPKcs þ) and M059J (DNAPKcs À) were incubated with 1 mmol/L gefitinib 1 hour before treatment with 15 Gy IR. Repair of IRinduced single and double SBs was measured by the alkaline comet assay over a 4-hour period. Figure 1 shows the percentage of the peak of IR-induced tail moment in these cells from three independent experiments. The percentage of SBs remaining was 7.78% AE 2.1% in the M059K at 4 hours after IR indicating near-complete repair of DNA damage (Fig. 1B) . In contrast, the NHEJ-deficient M059J cells showed 19.4% AE 5.6% of SBs remaining. Consistent with the role of the EGFR-DNAPKcs interaction in DNA repair modulation, repair of IR-induced DNA SBs at 4 hours was significantly impaired in M059K cells treated with gefitinib (15.51% AE 3.5%) when compared with M059K treated with IR alone. Strikingly, M059J cells treated with gefitinib also showed a significant amount of SBs unrepaired (35.89% AE 4.6%) when compared with M059J cells. These findings suggest that EGFR can promote DNA repair independently of DNAPKcs expression.
EGFR binds to ERCC1 following IR
To study protein interactions of endogenous EGFR following DNA damage, 10 mg of cell extracts from irradiated (20 minutes following 4 Gy IR) and nonirradiated M059K and M059J cells were immunoprecipitated with an anti-EGFR antibody. Stained bands were excised and analyzed by mass spectrometry. Only those proteins identified by at least two unique peptides were considered to be high confidence interactors. These were then grouped according to their pathways and the significance of this representation was calculated by the Ingenuity software ( Supplementary Fig.  S1A-S1D ). Having observed a higher inhibition of repair kinetics in the M059J cells (DNAPKcs À) following IR treatment in combination with gefitinib, the interaction of EGFR with genes involved in DNA repair was further investigated. Supplementary Data (Table S1 ) shows the list of high confidence EGFR interactors whose function is known to be involved in DNA damage response. Interestingly, both M059K and M059J showed the same list of EGFR interactors following IR with the exception of Topoisomerase 1 (Top1). ERCC1 was consistently detected as an EGFR interactor in two independent mass spectrometry experiments and given the abundance of XPF (known ERCC1 binding partner) the direct interaction of EGFR and ERCC1 was investigated.
To validate EGFR-ERCC1-XPF binding, immunoprecipitation of cell extracts from irradiated M059K and M059J cells was carried out. Immunoblotting showed a timedependent association of EGFR and ERCC1 peaking at 20 minutes following 4 Gy IR in both M059k and M059J cells ( Fig. 2A) . This interaction was also confirmed in a panel of cell lines following IR treatment. Cell extracts obtained 20 minutes following 4 Gy IR, from M059K, M059J, BON1, and QGP1 (two neuroendocrine pancreatic cancer cell lines; Fig. 2B and C), A431 (NSCLC) and A549 (NSCLC; Supplementary Fig. S2 ) were immunoprecipitated with an anti-EGFR antibody (Fig. 2B) or anti-ERCC1 antibody (Fig.  2C) , and blotted using anti-EGFR and anti-ERCC1 antibodies. These experiments confirmed EGFR-ERCC1 interaction in all cell lines 20 minutes following 4 Gy IR. Although ERCC1 associates with XPF, and the mass spectrometry data predicted XPF to be an interactor of EGFR, Western blot analysis revealed no interaction of XPF when cell extract were immunoprecipitated with EGFR. In contrast, cell extracts immunoprecipitated with ERCC1 showed constitutive binding with XPF. EGFR and ERCC1 colocalize and bind in the nucleus following IR treatment To further investigate the EGFR-ERCC1 interaction, cellular colocalization was analyzed following IR treatment by immunofluorescence. Confocal microscopy of M059K, M059J, BON1, or QGP1 cells showed EGFR nuclear accumulation 20 minutes following 4 Gy IR as previously described in other cell lines (28) , whereas ERCC1 staining showed only nuclear localization in all cell lines, independently of treatment (Fig. 3A) . This suggested that the EGFR-ERCC1 interaction would occur in the nucleus. Considering the technical difficulty to isolate 2 mg of nuclear lysate for all the cell lines 20 minutes following IR treatment, the Duolink proximity assay was performed to investigate further the localization of the EGFR-ERCC1 complex. This assay is utilized to determine in situ protein-protein interaction by using an immunofluorescence-based approach hence allowing detection of the complex and its cellular localization. M059K, M059J, BON1, and QGP1 cells were transfected with siRNA targeting ERCC1 or non-targeting siRNA and complex formation was investigated following IR treatment. All cell types transfected with control siRNA and treated with IR showed EGFR-ERCC1 nuclear interaction following IR. In contrast, cells transfected with ERCC1 siRNA showed no interaction as compared with the controls (Fig. 3B) . Non-targeting siRNA transfection showed no difference compared with untransfected cells (Supplementary Fig. S3A ). In line with previous studies on the effects of gefitinib on EGFR nuclear translocation and DNA repair, EGFR inhibition by gefitinib before IR treatment showed a reduction in the amount of nuclear EGFR-ERCC1 complex ( Supplementary Fig. S3B ). The nuclear pattern of this interaction induced by IR treatment suggests a role for this complex in DNA damage repair.
EGFR-ERCC1 interaction modulates DNA repair
To investigate the contribution of EGFR-ERCC1 complex to DNA repair in the presence and absence of DNAPKcs, SB repair kinetics of M059K and M059J cells depleted of EGFR, ERCC1, or both, by siRNA were assessed (Fig. 4) . Reduced expression of EGFR and ERCC1 was demonstrated from until 120 hours after transfection (Supplementary Fig. S4 ). After 48 hours, siRNA control and ERCC1 siRNA transfected cells were treated with 1 mmol/L gefitinib. Cells were treated with 15 Gy IR and DNA repair was examined 4 hours following treatment using the alkaline comet assay.
Non-targeting siRNA M059K and M059J transfected cells showed 14% AE 0.8% and 32.37% AE 1.7% of SBs remaining, respectively. Differences in residual SBs was observed between untransfected cells (Fig. 1) and control siRNAtransfected cells (Fig. 4) due to toxicity of siRNA transfection. Non-targeting siRNA M059K and M059J-transfected cells treated with gefitinib showed 27.93% AE 1.7% and 41.040% AE 2% of SBs remaining respectively. Significant inhibition of repair was observed in all cells following EGFR, ERCC1 or EGFR-ERCC1 knockdown. Higher levels of residual SBs were found in M059K cells transfected with ERCC1 siRNA (44.91% AE 1.2%) and treated with gefitinib (51.18% AE 3.9%), EGFR siRNA (50.97% AE 2.0%), or EGFR-ERCC1 siRNA (50.15% AE 5.0%). The inhibitor combination and the double knockdown showed no additive effect when compared with the single knockdown. Similarly, a higher percentage of residual SBs was also observed in the M059J cells transfected with ERCC1 siRNA (53.91% AE 17.1%) and treated with gefitinib (57.54% AE 3.3%) or EGFR siRNA (48.11% AE 1.4%), or EGFR-ERCC1 siRNA (58.36% AE 6.6%). Statistical analysis indicated that, also in the M059J, knockdown of EGFR-ERCC1 or combination with gefitinib had no additional effect when compared with the knockdown of either EGFR or ERCC1. This confirms that the role of EGFR and ERCC1 complex in repair of IRinduced DNA SBs is independent of DNAPKcs expression.
Phosphorylated H2AX (g-H2AX) provides a quantitative measurement of DSB induction and repair following low doses of IR treatment (29) . gH2AX foci were investigated over a period of 24 hours in transfected cell lines following 2 Gy IR (Fig. 5 ). M059K cells (Fig. 5A ) transfected with nontargeting siRNA show half the amount of g-H2AX foci at the 1-hour time point compared with M059J cells. These are reduced by 50% at 4 to 8 hours and at 24 hours M059K show levels of g-H2AX foci suggesting near complete DNA repair. In contrast, M059J cells show delayed disappearance of g-H2AX at all time points. This is in line with the role of DNAPKcs in NHEJ-mediated DNA repair. Depletion of ERCC1, EGFR, or EGFR-ERCC1 in M059K cells resulted in delayed kinetics of g-H2AX foci disappearance compared with control cells both at 4 and 8 hours following IR treatment. However, by 24 hours, these cells showed few residual g-H2AX foci suggesting near complete repair as compared to non-targeting siRNA transfected cells. In contrast, depletion of ERCC1, EGFR, or EGFR-ERCC1 in M059J cells, not only showed impaired kinetics of gH2AX foci disappearance at 8 hours but also persistence of the g-H2AX foci at 24 hours. There was no significant difference in the number of g-H2AX foci left at 24 following IR among the M059J cells depleted of ERCC1, EGFR, or EGFR-ERCC1. This suggests the involvement of both EGFR and ERCC1 in the same pathway with regards to SB repair, and a role for this complex independent of NHEJ.
EGFR-ERCC1 modulation of repair is necessary for cellular survival
DSBs are known to be particularly lethal for cell survival (30) . Having established that the knockdown of one or both the components of the EGFR-ERCC1 complex impairs (M059K) or inhibits (M059J) the repair of IR-induced DSB, growth inhibition of cells following IR treatment was determined by the MTT assay. M059K, M059J, BON1, and QGP1 cells were transfected with non-targeting, ERCC1, EGFR, and EGFR-ERCC1 siRNA either alone or in combination with gefitinib or a DNAPKcs inhibitor (NU7036). Survival of BON1 (Supplementary Fig. S5 ), M059K, QGP1, and M059J cells was then assessed 72 hours following IR treatment (Fig. 6A-C) . siRNA transfection and/or inhibitor combination alone did not affect overall survival of these cells (data not shown). Cells expressing DNAPKcs (M059K and QGP1) showed approximately 70% survival when ERCC1 knockdown and EGFR inhibition (by gefitinib or siRNA) were combined with IR treatment. These levels of survival were comparable with those obtained by DNAPK inhibition alone in combination with IR treatment. There was an additional decrease in survival when NU7026 was showed no difference in survival with treatment of gefitinib as a single agent which was highly statistically significant when compared with IR treatment alone. ERCC1 knockdown, EGFR knockdown, ERCC1 knockdown with gefitinib and the double knockdown in combination with IR treatment showed the highest decrease in survival in M059J cells. Addition of NU7026 did not show any further decrease in survival. There is, therefore, a relationship between the effect of EGFR-ERCC1 binding on DNA repair inhibition and the levels of overall survival following IR treatment. Knockdown or inhibition of the EGFR-ERCC1 complex has an additive effect with DNAPK inhibition in the survival of DNAPKcs-expressing cells. In the absence of DNAPKcs expression, inhibition of the EGFR-ERCC1 complex results in a further decrease in survival. This is in line with the result of DNA repair assays indicating a role for ERCC1-EGFR complex in SB repair independent of NHEJ.
To determine the significance of these effects on apoptosis, caspase-3 cleavage assay was performed in M059K, M059J, BON1, and QGP1 cells depleted of ERCC1, EGFR, or EGFR-ERCC1, 72 hours following IR treatment (Fig.   6D ). ERCC1 or EGFR knockdown cells treated with IR showed higher levels of caspase-3 cleavage compared with cells treated with IR only. In contrast with the results obtained by the growth inhibition assays, knockdown of both EGFR and ERCC1 showed an additive effect on apoptosis induction when compared with the single knockdown of EGFR or ERCC1. Consistent with the levels of caspase-3 cleavage, cleaved PARP accumulation increased following double knockdown of M059K, M059J, BON1, and QGP1 cells (Supplementary Fig. S4 ). The effect of EGFR-ERCC1 on survival cannot be explained by the induction of apoptosis alone, but it is likely involving other processes that result in cell death.
Discussion
Despite success in vitro, EGFR-targeted therapy has shown only modest improvement in patient survival in combination with chemotherapy, although there is evidence for success of combination with antibodies targeting EGFR in colorectal cancer. A pivotal study demonstrated synergism between radiation and cetuximab in head and neck cancer (31) but the mechanisms for these interactions remain unclear. A major goal is to identify potential biomarkers and the design of targeting approaches that aim to control primary and secondary responses to therapy.
We have previously established the importance of EGFR in modulating cellular response to cisplatin and IR treatment and demonstrated that EGFR enhances NHEJ via association with DNA-PKcs (11). This study highlights novel involvement of EGFR-ERCC1 binding in the repair of IR-induced SBs.
The understanding of an additional involvement of EGFR in DNA repair stemmed from two observations. We had firstly shown that abrogation of EGFR nuclear expression was sufficient to impair the repair of DNA strand breaks and cisplatin-induced ICLs. Cell expressing different EGFR mutants showed a variety of repair kinetics following IR treatment that could not just reflect EGFR-DNA-PKcs binding (11) . Second, we also observed that EGFR inhibition, in cells deficient in expression of DNAPKcs, showed higher inhibition of DNA repair when compared with IR treatment alone.
In addition to identifying and validating ERCC1 as an EGFR interactor, our mass spectrometry screen has identified a number of potential novel binding partners involved in DNA repair, including Top1 and Nucleolin (Supplementary Table S1 ). Interestingly, some of these show potential binding to EGFR independently of the DNA-damaging treatment suggesting a role for EGFR in basal DNA repair activity. Further validation is needed to confirm these findings; however, these data highlight the importance of investigating the role of EGFR in DNA repair. The ERCC1-XPF heterodimer is a central component of NER and is also required for the repair of ICLs via a mechanism independent of NER (18, 22, 23) . However, there are also reports indicating involvement of ERCC1-XPF in repair of DNA strand breaks (24, 32) . This complex is known to remove nonhomologous 3 0 termini of single-stranded DNA overhangs promoting single-strand annealing in yeast (33) . Recently, it has been shown that an alternative NHEJ pathway requires ERCC1 by facilitating DNA double strand break repair (24) . In line with our findings, ERCC1 involvement is shown to be independent of Ku86 and required for DSBs even when both NHEJ and HR can occur. Although ERCC1 associates with XPF, and the mass spectrometry data predicted XPF to be an interactor of EGFR, Western blot analysis did not reveal an interaction with XPF when cell extracts were immunoprecipitated with EGFR antibody. We are currently investigating this further.
While ERCC1 expression is exclusively nuclear, a fraction of cellular EGFR translocates to the nucleus following IR treatment. Our data show that this complex forms in the nucleus in response to IR-induced DNA damage, and is secondary to EGFR nuclear translocation (Fig. 3) . This is in line with studies on NER components where the ERCC1-XPF complex has been shown to assemble at the site of damage rather than being preassembled and scan long genomic sequence in search of DNA damage (34) .
The comet assay data on cells depleted of ERCC1 and/or EGFR expression clearly show a persistence of SBs. The high percentage of SBs left to repair at 4 hours is indicative of DNA repair inhibition when compared with the control cells. It is known that IR-induced gH2AX foci observed after 30 to 60 minutes following IR treatment represent the total number of persistent DSBs. While 50% of those are cleared within approximately 2 hours after, the remaining foci are cleared within 8 hours (35) . The kinetics of IR-induced foci disappearance in both control M059K and M059J are consistent with this model, and demonstrate the higher number of initial persistent DSBs in the M059J with no DNA-PKcs expression. The knockdown of ERCC1 and/or EGFR shows delayed repair in the M059K and inhibition of repair in the M059J. While M059K cells with either/or EGFR-ERCC1 knockdown reach levels of total foci clearance comparable with the control by 24 hours, M059J cells, with ERCC1 and/ or EGFR knockdown, not only show impaired kinetics but also persistence at 24 hours following IR treatment. This suggests that in the context of NHEJ-proficient cells, the EGFR-ERCC1 complex formation is still required for repair. In contrast, in cells with compromised DNAPK activity, EGFR-ERCC1 interaction is central to DNA repair. Interestingly, the levels of gH2AX foci are decreased in both EGFR and/or ERCC1 siRNA transfected cells at 1 hour following IR treatment. The kinetics of repair at later time points are, however, significantly slower compared with the control cells throughout all the later time points. This suggests that both EGFR and ERCC1 knockdown could partially inhibit the recruitment of gH2AX and therefore affect the efficiency and the rate of the DNA repair.
The nonadditive effect of the double knockdown in both cell lines, when compared with ERCC1 or EGFR single knockdown, suggests that these two proteins are part of the same pathway and that they exert similar functions in DNA SB repair (8) . This is further emphasized by the survival data, which mirror the EGFR-ERCC1 epistatic effect shown by the DNA repair assay. Overall survival of the M059K, M059J, BON1, QGP1 cells depleted of ERCC1 and/or EGFR expression also show additivity with DNAPKcs inhibition demonstrating that the ERCC1-EGFR complex is part of a NHEJ-independent mechanism. The survival levels in ERCC1 and EGFR single and double knockdowns are comparable with the levels of survival observed following DNA-PKcs inhibition alone. This demonstrates an important role for EGFR and ERCC1 as radioprotectors in cancer cells.
Studies on the ERCC1-XPF complex have revealed that the enzymatic nuclease activity is contained only in XPF, and although ERCC1 contains a central domain that resembles the nuclease domain contained in XPF, it lacks an active site (36) . Although we cannot rule out the possibility that both EGFR and ERCC1 may also affect DNA repair indirectly, their nuclear association in response to IR favors a more direct role in controlling the response to IR-induced strand breaks. Indeed, the additive effect of the double knockdown in apoptosis shows that both EGFR and ERCC1 do have other cellular roles (1, 37, 38) and that decreased in survival might be the consequence of caspase-independent mediated cell death which has been demonstrated to be modulated by inhibition of EGFR (39) .
We demonstrate that an EGFR-ERCC1 interaction is important for DNA repair kinetics and central for DNA repair in the absence of NHEJ. EGFR and ERCC1 expression have both been used as prognostic and predictive markers in clinical outcome of cancers including NSCLC (40) . While EGFR overexpression and somatic mutations have been shown to correlate with poor overall survival for both IR and platinum therapy (41), ERCC1 expression has been mostly linked clinically to cisplatin sensitivity (42) . This study shows interaction between EGFR and ERCC1 and suggests that their expression in tumor cells may have significant effects on outcome of EGFR inhibition in combination with chemotherapy and radiation.
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